ROIVW
Price:
$2.75
Market Cap:
$9.12B
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.[Read more]
Industry
Biotechnology
IPO Date
2021-09-27
Stock Exchange
NASDAQ
Ticker
ROIVW
According to Roivant Sciences Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 7.20B. This represents a change of 100.06% compared to the average of 3.60B of the last 4 quarters.
The mean historical Enterprise Value of Roivant Sciences Ltd. over the last ten years is 2.57B. The current 7.20B Enterprise Value has changed 27.93% with respect to the historical average. Over the past ten years (40 quarters), ROIVW's Enterprise Value was at its highest in in the September 2023 quarter at 8.09B. The Enterprise Value was at its lowest in in the March 2024 quarter at 2.34B.
Average
2.57B
Median
2.13B
Minimum
235.07M
Maximum
4.89B
Discovering the peaks and valleys of Roivant Sciences Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.98%
Maximum Annual Enterprise Value = 4.89B
Minimum Annual Increase = -68.65%
Minimum Annual Enterprise Value = 235.07M
Year | Enterprise Value | Change |
---|---|---|
2024 | 2.13B | -47.52% |
2023 | 4.06B | 165.33% |
2022 | 1.53B | -68.65% |
2021 | 4.89B | 1.98% |
The current Enterprise Value of Roivant Sciences Ltd. (ROIVW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.58B
5-year avg
2.57B
10-year avg
2.57B
Roivant Sciences Ltd.’s Enterprise Value is less than Roivant Sciences Ltd. (7.20B), greater than Jasper Therapeutics, Inc. (240.35M), greater than Humacyte, Inc. (574.42M), greater than eFFECTOR Therapeutics, Inc. (4.74M), greater than Reviva Pharmaceuticals Holdings, Inc. (33.37M),
Company | Enterprise Value | Market cap |
---|---|---|
7.20B | $9.12B | |
240.35M | $314.73M | |
574.42M | $566.49M | |
4.74M | $2.82K | |
33.37M | $40.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Roivant Sciences Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Roivant Sciences Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Roivant Sciences Ltd.'s Enterprise Value?
What is the highest Enterprise Value for Roivant Sciences Ltd. (ROIVW)?
What is the 3-year average Enterprise Value for Roivant Sciences Ltd. (ROIVW)?
What is the 5-year average Enterprise Value for Roivant Sciences Ltd. (ROIVW)?
How does the current Enterprise Value for Roivant Sciences Ltd. (ROIVW) compare to its historical average?